On World AIDS Day 2025, the World Health Organization (WHO) highlighted the urgent need to expand access to new HIV prevention tools and strengthen investment in essential services to maintain progress in the fight against AIDS.
The WHO release emphasized the role of long-acting injectable lenacapavir (LEN), which was recommended in July 2025 as an additional Pre-Exposure Prophylaxis (PrEP) option. LEN offers a long-acting, twice-yearly injectable option for HIV prevention.
The organization noted that reductions in international funding have disrupted HIV prevention, testing, and treatment services in many countries. This has affected access to community-led HIV programmes, including PrEP and harm reduction services for people who inject drugs.
WHO stressed that the combination of new prevention tools like injectable LEN and sustained investment in essential services is essential to maintain momentum in global HIV prevention efforts and continue progress toward ending the AIDS epidemic.
